Literature DB >> 30532659

Patterns of post-operative irradiation in breast cancer patients submitted to neoadjuvant chemotherapy.

Kennya Medeiros L de B Lima1, Allan A Lima Pereira2, Thiago B de Freitas1, Saulo Brito Silva2, Heloisa de Andrade Carvalho3,4, Max S Mano2,5, Gustavo Nader Marta1,4.   

Abstract

BACKGROUND/AIM: Post-operative radiation therapy (PORT) is associated with improvement in loco-regional control and survival rates in early breast cancer. However, the evidence of benefit in patients after treatment with neoadjuvant chemotherapy (NAC) is poor. We aimed to assess the impact of the type of surgery in the PORT plan and the role of the PORT fields in clinical outcomes in breast cancer patients who had undergone NAC followed by surgery.
MATERIALS AND METHODS: We performed a retrospective analysis of all non-metastatic breast cancer patients treated between 2008 and 2014 at our institution who had received NAC and PORT.
RESULTS: A total of 528 women were included of whom 396 were submitted to mastectomy or nipple-sparing/skin-sparing mastectomy. Most (92.8%) of the patients had locally advanced disease (clinical stage IIB to IIIC). All patients underwent irradiation for breast or chest wall. Most patients received PORT to the supraclavicular and axillary (levels II and III) nodes (87.1% and 86.4% for breast-conserving surgery and 95.1% and 93.8% for mastectomy and nipple-sparing/skin-sparing mastectomy, respectively). Irradiation of level I axillary and internal mammary nodes was uncommon. The disease-free survival and overall survival rates at 3 years were 72% and 85%, respectively. There were no statistically significant differences in clinical outcomes according to the use of nodal irradiation.
CONCLUSIONS: After NAC, most patients received irradiation of the breast/chest wall and axillary and supraclavicular nodes. In this setting, PORT to breast/chest wall with or without regional nodal irradiation was safe and effective, with acceptable disease-free and overall survival rates reported in this high-risk population.

Entities:  

Keywords:  Breast cancer; Neoadjuvant chemotherapy; Radiation therapy; Recurrence; Survival

Year:  2018        PMID: 30532659      PMCID: PMC6265518          DOI: 10.1016/j.rpor.2018.11.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  32 in total

1.  Post-mastectomy radiation therapy and overall survival after neoadjuvant chemotherapy.

Authors:  Olga Kantor; Catherine Pesce; Puneet Singh; Megan Miller; Jennifer Tseng; Chi-Hsiung Wang; David J Winchester; Katharine Yao
Journal:  J Surg Oncol       Date:  2017-01-13       Impact factor: 3.454

Review 2.  Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.

Authors:  Alfredo Berruti; Vito Amoroso; Fabio Gallo; Valentina Bertaglia; Edda Simoncini; Rebecca Pedersini; Laura Ferrari; Alberto Bottini; Paolo Bruzzi; Maria Pia Sormani
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

3.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

4.  The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.

Authors:  C G Rusthoven; R A Rabinovitch; B L Jones; M Koshy; A Amini; N Yeh; M W Jackson; C M Fisher
Journal:  Ann Oncol       Date:  2016-02-09       Impact factor: 32.976

5.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

6.  Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS).

Authors:  L Mauriac; G MacGrogan; A Avril; M Durand; A Floquet; M Debled; J M Dilhuydy; F Bonichon
Journal:  Ann Oncol       Date:  1999-01       Impact factor: 32.976

7.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Authors:  Philip M Poortmans; Sandra Collette; Carine Kirkove; Erik Van Limbergen; Volker Budach; Henk Struikmans; Laurence Collette; Alain Fourquet; Philippe Maingon; Mariacarla Valli; Karin De Winter; Simone Marnitz; Isabelle Barillot; Luciano Scandolaro; Ernest Vonk; Carla Rodenhuis; Hugo Marsiglia; Nicola Weidner; Geertjan van Tienhoven; Christoph Glanzmann; Abraham Kuten; Rodrigo Arriagada; Harry Bartelink; Walter Van den Bogaert
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

8.  Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.

Authors:  Allen M Chen; Funda Meric-Bernstam; Kelly K Hunt; Howard D Thames; Mary Jane Oswald; Elesyia D Outlaw; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Merrick I Ross; S Eva Singletary; Fredrick C Ames; Barry W Feig; Aysegul A Sahin; George H Perkins; Naomi R Schechter; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer.

Authors:  Lise Bech Jellesmark Thorsen; Birgitte Vrou Offersen; Hella Danø; Martin Berg; Ingelise Jensen; Anders Navrsted Pedersen; Sune Jürg Zimmermann; Hans-Jürgen Brodersen; Marie Overgaard; Jens Overgaard
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

10.  Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy.

Authors:  Amit K Garg; Julia L Oh; Mary Jane Oswald; Eugene Huang; Eric A Strom; George H Perkins; Wendy A Woodward; T Kuan Yu; Welela Tereffe; Funda Meric-Bernstam; Karin Hahn; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-12       Impact factor: 7.038

View more
  2 in total

1.  Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.

Authors:  Yanyu Zhang; Yaotian Zhang; Zhuang Liu; Zilan Qin; Yubing Li; Jiaming Zhao; Xinchi Ma; Qiankun Yang; Ning Han; Xue Zeng; Hong Guo; Na Zhang
Journal:  J Oncol       Date:  2021-01-24       Impact factor: 4.375

2.  The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study.

Authors:  Gustavo Nader Marta; Reem AlBeesh; Allan A Lima Pereira; Leandro Jonata Oliveira; Max S Mano; Tarek Hijal
Journal:  Breast       Date:  2020-08-29       Impact factor: 4.380

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.